Skip to content

Study · Not a test of the peptide alone · 2026

2 results

Peripheral nerve complications from medications utilised for weight loss: a systematic review.

O'Gorman C, O'Gorman M, Warren N

Journal of neurology3 Aug 2026

PMID42547656 (opens in a new tab)PMCIDPMC13433482 (opens in a new tab)DOI10.1007/s00415-026-14048-w (opens in a new tab)PepBankPUB-42547656
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

BackgroundThere is a global epidemic of obesity and in this context, the development of novel agents for weight loss has been timely. There have been emerging reports of peripheral nerve complications and this study aimed to systematically review all reported cases associated with medications used for weight loss.MethodsA systematic search of PubMed, Embase and CINAHL databases from inception to 30 June 2026 was performed to identify studies that report new-onset or worsening peripheral nerve complications. Independent screening was conducted by two authors. Data including demographics, medications, weight-loss parameters, neurological presentation and investigations. Descriptive statistics were used.ResultsThere were 19 studies, comprising 31 cases and one cohort (103 individuals) identified. All bar one were published from 2024. Of 31 individual cases median weight loss achieved was 20.4 kg (IQR 15.2) or 21.8% (IQR 16.4) of starting body weight. Median rate of weight loss was 3.7 kg/month (IQR 1.7), with symptom onset at 150 days (IQR 135). Semaglutide or tirzepatide were implicated in the majority (83%), and 67% had pre-diabetes/diabetes. Neurological presentations included fibular neuropathy (n = 10), lumbosacral radiculoplexus neuropathy (n = 9) and distal symmetric polyneuropathy (n = 7). Electrodiagnostic and imaging data were supportive of diagnosis.ConclusionsThere is a recent increase in peripheral nerve disorders associated with medical treatment of diabetes and obesity. To reduce the risk, it is recommended to ensure adequate nutritional status and avoid ultrarapid HbA1c and weight loss. Prospective studies are needed to determine incidence and confirm safe rates of weight loss and glycemic correction.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In 31 reported cases of peripheral nerve complications after weight-loss medication, semaglutide or tirzepatide (pooled) were implicated in 83%.

    In plain wordsIn reported cases of nerve problems after weight-loss drugs, semaglutide or tirzepatide were involved in most cases (83%).

    Peptide
    Semaglutide
    Outcome
    Not applicablePeripheral nerve complications with weight-loss medications
    Study

    n = 31

    Outcome group
    Adverse events · Nervous system and cognition

    Measurements

    Cases implicating semaglutide or tirzepatide
    83%
    31 cases

    Source sentences

    Summary
    Semaglutide or tirzepatide were implicated in the majority (83%), and 67% had pre-diabetes/diabetes.
    1 context sentence
    Summary · context
    A systematic search of PubMed, Embase and CINAHL databases from inception to 30 June 2026 was performed to identify studies that report new-onset or worsening peripheral nerve complications.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In 31 reported cases of peripheral nerve complications after weight-loss medication, semaglutide or tirzepatide (pooled) were implicated in 83%.

    In plain wordsIn reported cases of nerve problems after weight-loss drugs, semaglutide or tirzepatide were involved in most cases (83%).

    Peptide
    Tirzepatide
    Outcome
    Not applicablePeripheral nerve complications with weight-loss medications
    Study

    n = 31

    Outcome group
    Adverse events · Nervous system and cognition

    Measurements

    Cases implicating semaglutide or tirzepatide
    83%
    31 cases

    Source sentences

    Summary
    Semaglutide or tirzepatide were implicated in the majority (83%), and 67% had pre-diabetes/diabetes.
    1 context sentence
    Summary · context
    A systematic search of PubMed, Embase and CINAHL databases from inception to 30 June 2026 was performed to identify studies that report new-onset or worsening peripheral nerve complications.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.